Adia Med Sells 30% of Adia Labs for $1.5M, Cedes Equal Voting Control

summarizeSummary

Adia Med sold a 30% stake in its Adia Labs subsidiary for $1.5 million, giving the buyer equal voting power despite minority economic ownership.

check_boxKey Events · M&A and Partnerships · ADIA

• 30% Stake Sold for $1.5M

  Adia Med sold 30 units of Adia Labs LLC to Live Oak Health (QCM Biologics) for $50,000 per unit — $1 million cash plus a $500,000 promissory note at 7% interest.

• Equal Voting Despite Minority Stake

  Buyer receives 50% voting power on all member matters despite holding only 30% economic ownership, including control over budgets, debt, mergers, and manager appointments.

• Two-Year Option for 10 More Units

  Buyer holds an option until September 30, 2028 to purchase 10 additional units at $50,000 each ($500,000 total), which would reduce Adia Med's economic stake to 60%.

• Cash Infusion for Going-Concern Company

  The $1 million cash proceeds can be used for corporate purposes, providing runway for a company that reported a going-concern warning in its August 2026 10-Q.

auto_awesomeAnalysis · ADIA · Life Sciences

Adia Med sold 30% of its Adia Labs subsidiary to Live Oak Health (QCM Biologics) for $1.5 million — $1 million in cash and a $500,000 note. The unusual structure gives the buyer 50% voting power despite holding only 30% of the economic interest, meaning Adia Med loses unilateral control over its clinical and manufacturing operations. The deal also includes a two-year option for the buyer to acquire 10 more units for $500,000, which would reduce Adia Med's economic stake to 60% while maintaining the 50/50 voting split. For a company with a going-concern warning and a market cap under $10 million, the $1 million cash infusion provides near-term runway, but the governance concessions are significant.